| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 01/23/2013 | CN101735918B Selenium-rich health wine and production method thereof |
| 01/23/2013 | CN101716188B Animal pancreatic extract for preventing and curing diabetes |
| 01/23/2013 | CN101657192B Medicinal composition, food or drink having effect of enhancing parasympathetic nervous actions |
| 01/23/2013 | CN101641112B A novel combination of epimedium-derived-flavonoids-fractions for prevention of steroid-induced osteonecrosis |
| 01/23/2013 | CN101628913B Compound as estrogen-related receptor modulator and application thereof |
| 01/23/2013 | CN101616913B Fused cyclic compounds |
| 01/23/2013 | CN101608172B Transformant for reducing weight and fat and preparation method thereof |
| 01/23/2013 | CN101573357B 吲哚化合物 Indole compound |
| 01/23/2013 | CN101474300B Pharmaceutical composition for reducing blood sugar, blood fat and treating diabetes |
| 01/23/2013 | CN101210244B Neutrokine-alpha and Neutrokine-alpha splice variants |
| 01/22/2013 | US8357776 Composition for suppressing re-elevation of cholesterol, and usage thereof |
| 01/22/2013 | US8357701 Galactokinase inhibitors |
| 01/22/2013 | US8357686 Aryl-substituted polycyclic amines, method for the production thereof, and use thereof as a medicament |
| 01/22/2013 | US8357674 Analogues of cilostazol |
| 01/22/2013 | US8357670 Oligomeric compounds for the modulation of HIF-1A expression |
| 01/22/2013 | CA2560648C 1,1'-(1,2-ethynediyl)bis-benzene derivatives as ptp 1-b inhibitors |
| 01/22/2013 | CA2560595C Multi-vitamin and mineral nutritional supplements |
| 01/22/2013 | CA2560293C Substituted 1,4,8-triazaspiro[4.5]decan-2-on compounds |
| 01/22/2013 | CA2527691C Condensed ring compound |
| 01/22/2013 | CA2329267C A method of modulating the efficiency of translation termination and degradation of aberrant mrna involving a surveillance complex comprising human upflp, eucaryotic release factor 1 and eucaryotic release factor 3 |
| 01/17/2013 | WO2013008164A2 Method of treating atherosclerosis in high triglyceride subjects |
| 01/17/2013 | WO2013008162A1 Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease |
| 01/17/2013 | WO2013007792A1 Novel th2 polarizing compounds |
| 01/17/2013 | WO2013007676A1 Aminomethyl quinolone compounds |
| 01/17/2013 | WO2013007663A1 2-benzylsulfanyl[1,3,4]-oxadiazole derivatives, and medical use thereof |
| 01/17/2013 | WO2013007519A1 Polymorphs of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride |
| 01/17/2013 | WO2013007387A1 Novel fxr (nr1h4) binding and activity modulating compounds |
| 01/17/2013 | WO2013007167A1 Crystal form i of salt of dipeptidyl peptidase-iv inhibitor and preparation method and use thereof |
| 01/17/2013 | WO2012161518A3 Novel thiourea derivatives as activators of rorα and pharmaceutical composition containing same |
| 01/17/2013 | WO2012156998A3 Amorphous mirabegron and processes for crystal forms of mirabegron |
| 01/17/2013 | WO2012138919A3 Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
| 01/17/2013 | WO2012138599A3 Hepatocyte growth factor mimics as therapeutic agents |
| 01/17/2013 | WO2012109561A3 Tripeptide compositions and methods for treatment of diabetes |
| 01/17/2013 | US20130018105 Cis, 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one derivatives, substantially enantiomerically pure compositions and methods |
| 01/17/2013 | US20130018101 Salts of fenofibric acid and pharmaceutical formulations thereof |
| 01/17/2013 | US20130018095 Fumigillol Type Compounds and Methods of Making and Using Same |
| 01/17/2013 | US20130018083 Use of sirna targetting sipa1l1 for the reduction of adipogenesis |
| 01/17/2013 | US20130018074 New compounds |
| 01/17/2013 | US20130018073 Indole derivative |
| 01/17/2013 | US20130018071 Solid Forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| 01/17/2013 | US20130018070 Modulators of cystic fibrosis transmembrane conductance regulator |
| 01/17/2013 | US20130018068 Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 |
| 01/17/2013 | US20130018065 Processes for the preparation of key intermediate for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof |
| 01/17/2013 | US20130018057 Quinoline and Quinoxaline Derivatives as Kinase Inhibitors |
| 01/17/2013 | US20130018054 New compounds |
| 01/17/2013 | US20130018043 Aminomethyl quinolone compounds |
| 01/17/2013 | US20130018039 Imidazolyl-imidazoles as kinase inhibitors |
| 01/17/2013 | US20130018038 Chemical compounds |
| 01/17/2013 | US20130018036 Substituted indazole derivatives active as kinase inhibitors |
| 01/17/2013 | US20130018034 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
| 01/17/2013 | US20130018030 New compounds, pharmaceutical compositions and uses thereof |
| 01/17/2013 | US20130018017 Quinolinone derivatives as parp and tank inhibitors |
| 01/17/2013 | US20130018012 Lipid composition for improving brain function |
| 01/17/2013 | US20130018009 Anti-obesity product and its method of preparation |
| 01/17/2013 | US20130018005 Glycoside derivatives and uses thereof |
| 01/17/2013 | US20130017998 Novel modified galectin 9 proteins and use thereof |
| 01/17/2013 | US20130017994 Methods of Treating Glucose Metabolism Disorders |
| 01/17/2013 | US20130017993 Glycoside derivatives and uses thereof |
| 01/17/2013 | US20130017284 Compositions and methods for modulating metabolic pathways |
| 01/17/2013 | US20130017283 Compositions and methods for modulating metabolic pathways |
| 01/17/2013 | US20130017262 Immediate/delayed drug delivery |
| 01/17/2013 | US20130017256 Methods of treating hypertriglyceridemia |
| 01/17/2013 | US20130017255 Tamper Resistant Dosage Form Comprising an Adsorbent and an Adverse Agent |
| 01/17/2013 | US20130017250 Methods For High Density Lipoprotein Cholesterol Regulation |
| 01/17/2013 | US20130017226 TNF-A and TWEAK Dual Antagonist for the Prophylaxis and Treatment of Autoimmune Diseases |
| 01/17/2013 | US20130017212 THERAPEUTIC USE OF THE ß2m PROTEIN |
| 01/17/2013 | US20130017202 Pharmaceutical compositions and methods of treatment |
| 01/17/2013 | US20130017193 Antibody formulations |
| 01/17/2013 | US20130017188 Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses |
| 01/17/2013 | US20130017187 Pharmacological composition whereby statin and coq10 compounds are enhanced |
| 01/17/2013 | US20130017182 Multi-criteria optimized dietary supplement formulations |
| 01/17/2013 | US20130017181 Lipid-metabolism-ameliorating agent |
| 01/17/2013 | US20130017166 Protein-Poly(2-oxazoline) Conjugates for Enhanced Cellular Delivery and Transport Across Biological Barriers |
| 01/17/2013 | US20130017149 Pharmaceutical compounds |
| 01/17/2013 | CA2843777A1 Polymorphs of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride |
| 01/17/2013 | CA2841117A1 Method of treating atherosclerosis in high triglyceride subjects |
| 01/17/2013 | CA2841113A1 Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease |
| 01/17/2013 | CA2839395A1 Aminomethyl quinolone compounds |
| 01/16/2013 | EP2546330A1 Lactic acid bacterium-containing preparation |
| 01/16/2013 | EP2546255A1 Benzazepine compound |
| 01/16/2013 | EP2545964A1 Novel FXR (NR1H4) binding and activity modulating compounds |
| 01/16/2013 | EP2545939A2 Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring |
| 01/16/2013 | EP2545934A1 Aequorin-containing compositions and methods of using same |
| 01/16/2013 | EP2545930A1 Agent for controlling the increase and decrease of lactobacillus bifidus in colon |
| 01/16/2013 | EP2545055A1 Imidazo [1, 2 -a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases |
| 01/16/2013 | EP2545053A1 Azaisoquinolinone derivatives as nk3 antagonists |
| 01/16/2013 | EP2545025A1 Synthesis of alpha-tocopherolquinone derivatives, and methods of using the same |
| 01/16/2013 | EP2544696A1 Food comprising glucomannan, xanthan gum and alginate for the treatment of metabolic disorders |
| 01/16/2013 | EP2544668A2 Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| 01/16/2013 | EP2544542A1 Analgesic compounds, compositions, and uses thereof |
| 01/16/2013 | CN1838954B Glycogen synthase kinase-3 inhibitors |
| 01/16/2013 | CN102884047A 2-pyridone compounds |
| 01/16/2013 | CN102884037A Synthesis of alpha-tocopherolquinone derivatives, and methods of using the same |
| 01/16/2013 | CN102883737A Method of treatment of type 2 diabetes |
| 01/16/2013 | CN102883733A AGE production inhibitor |
| 01/16/2013 | CN102883726A Pharmaceutical formulations comprising 1-(beta-D-glucopyranosyl)-2 -thienylmethylbenzene derivatives as inhibitors of SGLT |
| 01/16/2013 | CN102875567A Piperazine compound and preparation and usage thereof |
| 01/16/2013 | CN102875523A 丹参丹酚酸f衍生物及药用用途 Salvia Sal f derivatives and medicinal uses |
| 01/16/2013 | CN102875518A Genipin methyl ether, preparation method and medicine application thereof |
| 01/16/2013 | CN102875517A Mollugin and preparation method and application thereof |